Drugs / Third-generation anti-CD123 CAR-T cells
Third-generation anti-CD123 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04014881 | Jul 2019 → Jul 2021 | acute myeloid leukemia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Third-generation anti-CD123 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04014881 ↗ |
| Modality | Cell therapy | “anti-CD123 CAR-T cells” NCT04014881 ↗ |